Browse News
Filter News
Found 45 articles
-
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting
5/8/2023
Cognito Therapeutics announced today two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting, held May 7-10 in Boston, MA.
-
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances
4/17/2023
Cognito Therapeutics , today announced executive leadership team appointments with Ralph Kern, M.D., as Chief Medical Officer and Kim Kwan as Chief Technology Officer who has been promoted from VP of Engineering.
-
Cognito Therapeutics Announces Gamma-Frequency Sensory Stimulation Decreases Brain Atrophy in Patients with Alzheimer’s Disease at AD/PD 2023
3/30/2023
Cognito Therapeutics, today announced neuroimaging results evaluating the effects of the company’s non-invasive neuromodulation medical device, which delivers proprietary gamma frequency light and sound stimulation in participants with Alzheimer's disease (AD).
-
Cognito Therapeutics Raises $73M Series B to Advance Neurotechnology Platform for Alzheimer’s Disease
3/22/2023
Cognito Therapeutics announced today a $73M Series B financing round led by FoundersX Ventures with participation from all existing investors.
-
Cognito Therapeutics Announces First Patient Enrollment in US Pivotal Study HOPE
2/21/2023
Cognito Therapeutics , a clinical-stage neurotechnology company, announced today the first patient enrollment in its US pivotal study (HOPE), designed to demonstrate the safety and efficacy of its proprietary non-invasive stimulation device CogTx-001 in patients with Alzheimer’s Disease.
-
Cognito Therapeutics to Present Clinical Data Evaluating Gamma Frequency Neuromodulation in Alzheimer’s Disease at 2022 CTAD Conference
10/31/2022
Cognito Therapeutics announced today it has been selected to present clinical data from its proprietary gamma sensory stimulation in patients with Alzheimer’s Disease, at the 2022 Clinical Trials in Alzheimer's Disease (CTAD), held November 29 - December 2, in San Francisco, CA.
-
Biogen and others are seeing the value in, particularly, non-prescription digital therapeutics, as complementary companion therapies to disease-modifying drugs.
-
Cognito Therapeutics Announces Proprietary Gamma Sensory Stimulation for 6-Months Reduces White Matter Atrophy in Alzheimer’s Disease Patients
8/1/2022
Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimer’s Disease, according to new data presented at the Alzheimer’s Association International Conference 2022.
-
Cognito Therapeutics Announces Data Presentations at the Alzheimer’s Association International Conference 2022
7/13/2022
Cognito Therapeutics , a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts and an oral presentation at the Alzheimer’s Association International Conference ® 2022 (AAIC ® ).
-
Altoida Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Predictive Biomarkers
5/16/2022
Altoida announced it has joined the Digital Medicine Society’s Alzheimer’s Disease and Related Dementias Digital Measures Development Project to support the advancement of its precision neuro-biomarkers platform.
-
Cognito Therapeutics Joins Digital Medicine Society’s (DiMe) Alzheimer's Disease and Related Dementias Project to Advance Next-Generation Clinical Measures
5/9/2022
Cognito Therapeutics today announced it has joined the Digital Medicine Society’s (DiMe) Alzheimer’s Disease and Related Dementias (ADRD) Digital Measures Development Project to support the advancement of its late-stage disease-modifying therapeutics pipeline for neurodegenerative diseases.
-
Advances in Biomarkers For Neurodegenerative Disease
4/11/2022
Neurodegenerative disease refers to a range of partly inherited conditions that destroy the neurons in the human brain due to the progressive damage of the nerve cells caused by diseases.
-
Akili to Speak at SXSW 2022 on Building a New Class of Disease-Modifying Digital Therapeutics
3/10/2022
Akili Interactive announced that co-founder and Chief Executive Officer, Eddie Martucci, will participate in a panel discussion at SXSW 2022, a conference that convenes a global community of digital creatives with a shared pursuit of forward-thinking, cutting-edge ideas.
-
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
3/8/2022
Cognito Therapeutics and Aetion announced a strategic partnership to develop a validated predictive model to identify patients with rapidly progressing mild cognitive impairment and Alzheimer’s disease.
-
Robert Califf became the new commissioner of the U.S. Food & Drug Administration and emphasized the use of real-world evidence (RWE) in Agency decisions.
-
Cognito Therapeutics Announces Presentations for Novel Therapeutic in Alzheimer’s Disease at the 2022 American Academy of Neurology (AAN) Conference
3/3/2022
Cognito Therapeutics, a pioneer in developing disease-modifying therapeutic interventions for neurodegenerative diseases, today announced the acceptance of two research abstracts, including one which was selected for a presentation at the “Neuroscience in Clinic” session, at the American Academy of Neurology Conference.
-
Cognito Therapeutics to Present Virtual Symposium “Predicting Alzheimer’s Disease Progression with Neurophysiological Markers” at 2022 AD/PD Conference
3/1/2022
Cognito Therapeutics announced today it will present a virtual symposium featuring a panel of leading neuroscientists to discuss neurophysiological markers in Alzheimer’s Disease progression.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment
1/27/2022
Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognito’s breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).
-
14th Annual Biotech Showcase™ Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually
1/20/2022
In its 14th year, Biotech Showcase™, co-produced by Demy-Colton and EBD Group, welcomed over 2,400 attendees, nearly a 10 percent increase from last year, together with over 860 investors, and 320 presenting companies.